P latelet-derived growth factor (PDGF)-BB is known as a multifunctional growth factor capable of stimulating various quiescent cells to proliferate. Accumulating evidence indicates that PDGF-BB is involved in various vascular diseases by stimulating vascular smooth muscle cell (SMC) proliferation, as reviewed. 1 However, the mechanism underlying PDGF-induced vascular SMC proliferation is not fully understood. In vascular proliferative diseases, entry into the progression of vascular cells through the cell cycle is thought to be a key event, 2 and PDGF-BB, through activation of the ␤-PDGF receptor, is a critical mediator of the lesion formation after vascular injury. 3 Therefore, detailed investigation into the molecular mechanism underlying PDGF-BBinduced vascular SMC proliferation is essential not only to elucidate the mechanism of vascular diseases but also to develop a new therapeutic strategy for vascular diseases.
The mitogenic action of PDGF-BB is initiated by its interaction with PDGF-BB receptor. Receptor-mediated relocation of cytoplasmic proteins to the inner surface of the plasma membrane, accompanied by subsequent tyrosine phosphorylation, results in the stimulation of multiple signaling pathways, including activation of SHP-2, Src, phospholipase C-␥, Ras, protein kinase A, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase, ultimately leading to DNA synthesis, as reviewed. 4, 5 PDGF also induces the immediate-early gene, including c-jun, c-fos, and c-myc. However, the exact role of these multiple signaling cascades activated by PDGF in SMC proliferation is unclear.
The proto-oncogene c-Jun, known as a component of activator protein (AP)-1, is implicated in the regulation of various gene expressions and of cell proliferation, transformation, differentiation, and apoptosis. It is also clear that the role of c-Jun in cellular responses depends on the cell type and the context of other regulatory influences that the cell is receiving, as reviewed. 6 Overexpression of c-Jun is shown to induce apoptosis in 3T3 fibroblasts 7 and triggers apoptosis in vascular endothelial cells, 8 whereas in cultured fibroblasts and hepatoblasts, c-Jun acts as a positive regulator of cell growth by using c-Jun knockout mice. 9 -11 However, it remains to be determined whether c-Jun participates in PDGF-BB-induced vascular SMC proliferation. To elucidate the possible contribution of c-Jun to vascular SMC proliferation by PDGF-BB, we constructed a recombinant adenovirus containing the dominant-negative mutant of c-Jun (Ad-DNc-Jun) and infected rat aortic SMCs with this recombinant adenovirus to inhibit endogenous c-Jun. We obtained the first evidence that c-Jun participates in PDGF-BB-induced vascular SMC proliferation and found a novel mechanism: the downregulation of p27
Kip1 by c-Jun is involved in PDGF-BBinduced vascular SMCs proliferation.
Methods

Reagents and Cells
Human recombinant PDGF-BB was purchased from Sigma Chemical Co. Rat aortic SMCs were prepared from thoracic aortas of male Sprague-Dawley rats (Clea Japan, Tokyo, Japan) by using the collagenase digestion method and cultured as described. 12 For all experiments, rat aortic SMCs from passages 4 to 7 were used. SMCs were grown to 70% to 80% confluence and then made quiescent by incubation with DMEM containing 0.1% FBS for 48 hours before the addition of PDGF-BB.
Construction of Ad-DN-c-Jun
The dominant-negative mutant of c-Jun, called TAM67, was generated by removal of the transactivational domain of amino acids 3 to 122 of wild-type c-Jun 13 by polymerase chain reaction. TAM67 has the DNA binding domain of wild-type c-Jun. Recombinant replication-defective E1 and E3 adenoviral vectors expressing the TAM67 gene (Ad-DN-c-Jun) were constructed by using an adenovirus expression vector kit (Takara Biomedicals), according to the method of Miyake et al. 14 cDNA encoding TAM67 was placed into a cassette cosmid vector, PaxCAwt, which possesses the CAG promoter, 15 composed of a cytomegalovirus enhancer, chicken ␤-actin promoter, and rabbit ␤-globin poly(A) signal. A recombinant adenovirus was constructed by in vitro homologous recombination in 293 cells by using the above cosmid vector, PaxCAwt, containing TAM67 cDNA and the adenovirus DNA-terminal protein complex. Recombinant adenoviruses containing bacterial ␤-galactosidase gene (Ad-LacZ) were also constructed as negative controls of Ad-DN-cJun, in the same way as Ad-DN-c-Jun. The titer of the virus was determined by limiting dilution in 293 cells and expressed as plaque-forming units.
Adenovirus-Mediated Gene Transfer to SMCs
In vitro gene transfer to aortic SMCs was carried out by incubation with the adenoviral vector with a multiplicity of infection (MOI) of 50, 100, 250, or 500 in DMEM containing 0.1% FBS for 1 hour at 37°C and 5% CO 2 /95% air. Then, SMCs were made quiescent for 48 hours before being assessed for the expression and the effect of the transferred gene.
An expanded Methods section is available online at http://atvb.ahajournals.org.
Results
Aortic SMC Proliferation and Increase in AP-1 DNA Binding Activity by PDGF-BB As estimated by [ 3 H]thymidine incorporation, treatment of aortic SMCs with PDGF-BB for 24 hours increased the rate of DNA synthesis in a dose-dependent manner, and 10 ng/mL of PDGF-BB exerted an almost maximal effect (see online Figure I -A,, which can be accessed at http://atvb.ahajournals. org). Therefore, PDGF-BB stimulation of SMCs was carried out at a dose of 10 ng/mL in all experiments, except for the experiment of dose response. The addition of 10 ng/mL PDGF-BB significantly increased SMC numbers with time (see online Figure I In preliminary experiments, we examined the transgene expression of ␤-galactosidase in SMCs infected with AdLacZ at an MOI of 50, 100, 250, or 500 by using in situ ␤-galactosidase staining and found that the transgene expression of ␤-galactosidase in SMCs reached a plateau with the adenoviral infection at 250 MOI (data not shown). Further- Figure 1B) . To confirm the specificity of this increased AP-1 activity that was due to Ad-DN-c-Jun, we examined the serum response element (SRE), nuclear factor (NF)-B, and stimulatory protein-1 (Sp1) DNA binding activity. Figure 2 shows that Ad-DN-c-Jun infection did not affect the SRE, NF-B, and Sp1 DNA binding activity. Moreover, as shown by dual luciferase assay in Figure 3 , PDGF-BB increased AP-1 transcriptional activity in aortic SMCs, and this increase was significantly inhibited by Ad-DN-c-Jun but not by Ad-Lac Z. Furthermore, Ad-DNc-Jun infection did not change SRE and NF-B transcriptional activity, indicating specific blockade of AP-1 transcriptional activity by Ad-DN-c-Jun.
Ad-DN-c-Jun Attenuates PDGF-BB-Induced Proliferation Through G 1 Arrest
Infection of aortic SMCs with Ad-DN-c-Jun at 250 MOI diminished the PDGF-BB-induced increase in [ 3 H]thymidine incorporation by 42%, whereas Ad-LacZ had no effect ( Figure 4A ). Ad-DN-c-Jun or Ad-LacZ did not affect [ 3 H]thymidine incorporation in SMCs without PDGF-BB stimulation. Ad-DN-c-Jun also inhibited the PDGF-BB-induced increase in cell number by 38% ( Figure 4B ), whereas this increase was not affected by Ad-LacZ, even at 500 MOI ( Figure 4B ). Neither adenoviral infection affected the SMC number without PDGF-BB stimulation (data not shown). 
Effects of DN-c-Jun on p27
Kip1 , p21 Cip1 , p53, and Cyclin-Dependent Kinase 2 Activity
As shown in Figure 6A , PDGF-BB exposure of aortic SMCs downregulated p27
Kip1 in a time-dependent manner, which is consistent with the findings by Servant et al. 16 On the other hand, PDGF-BB increased p21
Cip1 in a time-dependent manner and did not change p53 levels.
As shown in Figure 6B , this downregulation of p27 Kip1 in SMCs exposed to PDGF-BB (16 hours) was prevented by Ad-DN-c-Jun (250 MOI) by 62% but not by Ad-LacZ. In SMCs not subjected to PDGF-BB stimulation, neither AdLacZ nor Ad-DN-c-Jun significantly affected p27 Kip1 . p27
Kip1 is known to inhibit the cyclin-regulatory subunit and catalytic cyclin-dependent kinase (Cdk) complex activity, including cyclin E/Cdk2 activity. Cyclin E/Cdk2 activity is essential for entry into S phase. 17, 18 To further elucidate the molecular mechanism of PDGF-BB-induced SMC proliferation, an immunoprecipitation study with anti-cyclin E antibody or anti-p27
Kip1 antibody was performed to determine cyclin E-associated p27
Kip1 levels. As shown in Figure 6C , the addition of PDGF-BB (10 ng/mL, 16 hours) significantly decreased cyclin E-associated p27
Kip1 levels, which is in good agreement with the results of Servant et al. 16 Compared with Ad-LacZ, Ad-DN-c-Jun infection significantly prevented the PDGF-BB-induced decrease in cyclin E-associated p27 Kip1 . Furthermore, Cdk2 activity was measured by the immune complex kinase assay by using histone H1 as a substrate. As shown in Figure 6D , treatment of aortic SMCs with PDGF-BB (10 ng/mL, 16 hours) activated Cdk2, and this activation was significantly blocked by Ad-DN-c-Jun but not by Ad-Lac Z. Neither adenoviral infection affected the Cdk2 activity in aortic SMCs not subjected to PDGF-BB treatment.
As shown in Figure 6E , Ad-DN-c-Jun did not affect p21
Cip1 or p53 levels in SMCs with or without PDGF-BB (16 hours).
In addition, we examined the effects of Ad-DN-c-Jun on the protein expression of cyclin D1, cyclin E, Cdk2, and Cdk4. Compared with Ad-LacZ, Ad-DN-c-Jun did not prevent an increase in cyclin D1, cyclin E, Cdk2, or Cdk4 proteins by PDGF-BB (data not shown).
Discussion
Accumulating evidence supports the notion that PDGF is involved in a variety of vascular diseases by stimulating vascular SMC proliferation, as reviewed. 1 We and other groups of investigators have shown that tyrosine phosphorylation of the PDGF receptor, particularly the PDGF ␤-receptor activated by PDGF-BB, is enhanced in ballooninjured arteries, hypertensive aortas, and other vascular lesions. 19, 20 Vascular SMC proliferation by PDGF in vitro is mediated by multiple intracellular signaling molecules, such as Ras, protein kinase C, Src, or phosphatidylinositol 3-kinase, as reviewed. 5 In the present study, using an adenoviral expression vector containing TAM67 (a dominantnegative c-Jun gene), we investigated the novel mechanism responsible for PDGF-BB-induced vascular SMC proliferation and obtained the first evidence that c-Jun partially but significantly contributes to PDGF-BB-induced vascular SMC proliferation through the downregulation of p27 Kip1 , the activation of Cdk2, and the subsequent induction of G 1 /S transition.
As recently reviewed, 6 c-Jun exerts diverse biological functions, including cell proliferation, transformation, differentiation, and apoptosis, depending on the cell type and the context of other regulatory influences that the cell is receiving. c-Jun plays a critical role in the proliferation of cultured fibroblasts and hepatoblasts, 9 -11 whereas c-Jun overexpression is shown to induce apoptosis in 3T3 fibroblasts 7 and trigger apoptosis in vascular endothelial cells. 8 However, the biological role of c-Jun in vascular SMCs remains to be determined. We have previously reported that AP-1 binding activity, composed of c-Jun, is significantly enhanced in injured rat artery by balloon angioplasty 21 and angiotensin II-mediated hypertension, 22 suggesting that c-Jun may play 
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some role in various vascular diseases. These findings encouraged us to elucidate the role of c-Jun in PDGF-BBinduced vascular SMC proliferation. The use of adenoviruses containing the dominant-negative c-Jun gene allowed us to specifically suppress endogenous c-Jun. To our knowledge, the present work provides the first evidence that c-Jun participates in PDGF-BB-induced vascular SMC proliferation. Furthermore, our recent work, 23 in which we used a dominant-negative mutant of extracellular signal-regulated kinase (ERK) or c-Jun amino-terminal kinase (JNK), indicates that ERK and JNK are involved in vascular SMC proliferation. Taken together with the fact that these kinases can activate AP-1, 24 these findings suggest that c-Jun may participate in ERK-or JNK-induced SMC proliferation. The progression that exit cells from G 1 phase into S phase is regulated by the activation of multiple holoenzymes composed of cyclin-regulatory subunit and catalytic Cdk. 2 Particularly, cyclin E/Cdk2 activity is essential for entry into S phase. 17, 18, 25 Cyclin-dependent kinase inhibitor (CKI) p27
Kip1 has been initially characterized as an inhibitor of cyclin E/Cdk2 activation that is responsible for retinoblastoma gene product phosphorylation. 26, 27 Ectopic expression of p27 Kip1 causes cell cycle arrest in G 1 phase, 26 and conversely, antisense inhibition of p27
Kip1 expression suppresses quiescence in fibroblasts. 28, 29 The expression of p27
Kip1 is increased in serum-starved or density-arrested cells and in cells exposed to antiproliferative signals, such as transforming growth factor-␤1. 30 -32 In contrast, p27
Kip1 levels decline in response to mitogenic factors, 28, 31, 33 and overexpression of p27 Kip1 cDNA in vascular SMCs inhibits mitogen-stimulated [
3 H]thymidine incorporation. 34 Importantly, downregulation of p27
Kip1 during late G 1 phase plays an important role in cell cycle progression from G 1 to S phase. 28, 32 Recently, Servant et al 16 reported that PDGF-BB downregulates p27
Kip1 and then enhances Cdk2 activity in the late G 1 phase of mitogenic response in vascular SMCs, whereas in angiotensin IIinduced hypertrophic response, neither enhanced Cdk2 activity nor downregulation of p27
Kip1 is found, showing that the downregulation of p27
Kip1 is important in vascular SMC proliferation. However, the mechanism responsible for the downregulation of p27
Kip1 by PDGF-BB remains to be determined. Therefore, in the present study, we investigated the role of c-Jun in PDGF-BB-induced downregulation of p27 Kip1 in vascular SMCs. Our present results showed that Ad-DN- , and p53 protein levels from SMCs exposed to PDGF-BB for the indicated times were determined by Western blot analysis. The experiments were repeated twice, and similar results were obtained. B, Aortic SMCs, infected with Ad-DN-c-Jun or Ad-Lac Z (250 MOI) or not infected with adenoviruses, Ad (Ϫ), were exposed to PDGF-BB (10 ng/mL, 16 hours) and then subjected to Western blot analysis with anti-p27
Kip1 antibody or anti-␣-tubulin antibody. Each value represents meanϮSEM. *PϽ0.05 vs PDGF-BB (Ϫ). The experiments were repeated 3 times, and similar results were obtained. C, Detergent lysates of aortic SMCs with or without prior adenovirus infection, exposed to PDGF-BB (10 ng/mL, 16 hours) or not, were subjected to immunoprecipitation (IP) with anti-cyclin E antibody or antip27 Kip1 antibody and analyzed by Western blotting with either antibody. The experiments were repeated 3 times, and similar results were obtained. D, The phosphotransferase activity of Cdk2 was determined by protein kinase assay, immunoprecipitating with Cdk2 antibody, and using histone H1 as substrate, as described in detail in experimental procedures. The experiments were repeated twice, and similar results were obtained. E, Western blot analysis was performed with antibodies to p27 Kip1 , p21 Cip1 , and p53. The experiments were repeated twice, and similar results were obtained.
c-Jun infection of vascular SMCs prevented PDGF-BBinduced p27
Kip1 downregulation ( Figure 6B ) and inhibited a PDGF-BB-induced decrease in cyclin-E/Cdk2 complex-associated p27
Kip1 ( Figure 6C ), leading to the blockade of Cdk2 activation ( Figure 6D ) and the subsequent cell cycle arrest in G 1 phase ( Figure 5) . Thus, the present work provided the first evidence that there is a link between c-Jun and p27
Kip1 in the regulation of mitogenic cell progression and that c-Jundependent p27
Kip1 downregulation participates in PDGFinduced proliferation of vascular SMCs.
Although the Kip/Cip family of CKIs, including p27
Kip1 and p21 Cip1 , are thought to be negative regulators of the cyclin/Cdk complex, there have been some reports indicating that the CKIs positively regulate cyclin/Cdk activation. 31, 32, 35, 36 Recently, CKI p21
Cip1 has been reported to exhibit permissive effects on PDGF-BB-induced vascular SMC cycle progression, as shown by the fact that transfection of several lines of vascular SMCs with p21
Cip1 antisense decreased the association of cyclin D1/Cdk4 but not cyclin E/Cdk2 and resulted in the inhibition of PDGF-BB-induced proliferation. 37 In the present study, we found that PDGF-BB increased p21
Cip1 in a time-dependent manner within 24 hours, which is in good agreement with the previous report. 37 However, Ad-DN-c-Jun infection of aortic SMCs did not significantly affect the PDGF-BB-induced increase in p21 Cip1 ( Figure 6D ), thereby providing no evidence for the involvement of p21
Cip1 in c-Jun-dependent vascular SMC proliferation by PDGF-BB.
Previous reports have shown that c-Jun-mediated cell proliferation is associated with p53 in mouse embryo fibroblasts 38 and with cyclin D1 in NIH 3T3 mouse fibroblasts. 39 Nevertheless, in vascular SMCs, the present study showed no effect of PDGF-BB on p53 protein levels ( Figure 6A ) and no alteration of p53 levels by Ad-DN-c-Jun ( Figure 6D ), providing no evidence for the important role of p53 in c-Jundependent SMC proliferation by PDGF-BB. In the present study, we also examined whether the regulation of cyclin D1, cyclin E, Cdk2, and Cdk4 protein levels is involved in this c-Jun-mediated proliferation and found no contribution of c-Jun to the PDGF-BB-induced increase in these protein levels. Thus, in vascular SMCs, p27
Kip1 seems to specifically play a pivotal role in c-Jun-dependent G 1 /S transition and proliferation induced by PDGF-BB.
The present study did not allow us to elucidate the inhibitory mechanism of PDGF-induced p27 Kip1 downregulation by DN-c-Jun. Generally, p27
Kip1 levels are controlled by various mechanisms, including (1) posttranscriptional mechanisms, such as the ubiquitin-proteasome pathway and the ubiquitin-independent processing pathway, 40 (2) the transcriptional mechanism, 16 and (3) the phosphorylation of p27
Kip1 by activated cyclin E/Cdk2. 41 However, further study is needed to elucidate which mechanism(s) participates in the inhibition of PDGF-induced p27
Kip1 downregulation by DN-c-Jun.
In conclusion, c-Jun plays a pivotal role in PDGF-BBinduced vascular SMC proliferation, which is mediated by CKI p27 Kip1 . Our work provides not only a new insight into the molecular mechanism underlying PDGF-induced vascular SMC proliferation but also a new therapeutic approach for targeting the cell cycle in proliferative vascular diseases. 
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